16.11.2012 Views

251 286 - Biotech Bayern

251 286 - Biotech Bayern

251 286 - Biotech Bayern

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

22<br />

The BioTech Region Munich-Martinsried<br />

Prompted by its victory in the 1996 Bio-Regio Competition organised by the Federal Ministry of Education and Research,<br />

the Munich BioTech Region has developed into one of the leading clusters within Europe. Today, Munich leads Germany as<br />

regards the number of companies, employees and, most of all, the number of drugs in clinical development.<br />

Especially in the field of therapeutics and diagnostics, the region has become Germany's most important location.<br />

The central network coordinator for this cluster is BioM <strong>Biotech</strong> Cluster Development GmbH.<br />

The Munich BioTech Region: an international reputation, successful<br />

companies, a strong medical drugs pipeline<br />

The well-functioning network of science, industry and<br />

politics provides the biotechnology companies with a<br />

decisive locational advantage that has enabled the Munich<br />

BioTech Region to develop into Germany's leading biotechnology<br />

cluster. With more than 190 companies and more<br />

than 13,000 employees in the Life Science sector, and with<br />

two universities (which just recently joined the ranks of<br />

Germany's elite universities), two universities of applied<br />

sciences, the Max Plank Institutes of Biochemistry, Neurobiology<br />

and Psychiatry, the Helmholtz Research Center for<br />

Environmental Health, as well as further renowned institutes<br />

and organizations, the region offers an outstanding environ-<br />

Martinsried<br />

ment for innovations. The small and medium-sized biotechnology<br />

companies focus on so-called “red biotechnology”,<br />

especially on research and development in the field of<br />

diagnostics and therapeutics. Small and medium sized<br />

enterprises (SMEs) from Munich are at the very forefront of<br />

drug development throughout Germany – two products<br />

from MediGene have received marketing approval, further<br />

products have already been approved in other countries and<br />

are expected to receive approval in Germany in 2008. Eight<br />

companies are listed on the stock exchange, among them<br />

MorphoSys, one of the region's largest companies and one<br />

of those with the highest turnover.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!